| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.24 | 5e-11 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-10 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-10 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-10 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-10 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.21 | 9e-10 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.2 | 9e-10 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-09 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-09 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-09 |